Company intelligence / Profile preview

Immunochina Pharmaceuticals

Beijing, Beijing, Chinabiospace.com ↗
Ownership
Private
Development stage
Phase 1
01

Overview

Immunochina Pharmaceuticals (Imunopharm) is a leading Chinese clinical-stage biopharmaceutical company specializing in innovative gene and cell therapies—primarily CAR-T—for the treatment of malignant tumors. The company has presented positive clinical data at major international conferences such as ASCO and ASH. It holds seven China INDs for its pipeline products targeting both hematologic malignancies and solid tumors. Its lead product IM19 has received multiple IND approvals for relapsed/refractory B-cell acute lymphocytic leukemia and non-Hodgkin's lymphoma.

Therapeutic areas
OncologyImmunology
Modalities
CAR-T cell therapyGene therapyCell therapy
Industry
Biotech
02

Drug pipeline

22 assets

IM19

2

21 more assets in the full pipeline.

Request access →
03

Partnerships

EdigeneSimcere PharmaceuticalPeking University Third HospitalBeijing Cancer Hospital

Beyond the preview

Go deeper on Immunochina Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunochina Pharmaceuticals.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call